Skip to main content

Advertisement

SpringerLink
Log in

IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Cytokine-induced killer (CIK) cells are T cell derived ex vivo expanded cells with both NK and T cell properties. They exhibit potent anti-tumor efficacy against various malignancies in preclinical models and have proven safe and effective in clinical studies. We combined CIK cell adoptive immunotherapy with IL-12 cytokine immunotherapy in an immunocompetent preclinical breast cancer model. Combining CIK cells with IL-12 increased anti-tumor efficacy in vivo compared to either therapy alone. Combination led to full tumor remission and long-term protection in 75% of animals. IL-12 treatment sharply increased the anti-tumor efficacy of short-term cultured CIK cells that exhibited no therapeutic effect alone. Bioluminescence imaging based in vitro cytotoxicity and in vivo homing assays revealed that short-term cultured CIK cells exhibit full cytotoxicity in vitro, but display different tumor homing properties than fully expanded CIK cells in vivo. Our data suggest that short-term cultured CIK cells can be “educated” in vivo, producing fully expanded CIK cells upon IL-12 administration with anti-tumor efficacy in a mouse model. Our findings demonstrate the potential to improve current CIK cell-based immunotherapy by increasing efficacy and shortening ex vivo expansion time. This holds promise for a highly efficacious cancer therapy utilizing synergistic effects of cytokine and cellular immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Alvarnas JC, Linn YC, Hope EG, Negrin RS (2001) Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 7:216–222

    Article  PubMed  CAS  Google Scholar 

  2. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3:409–417

    PubMed  CAS  Google Scholar 

  3. Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, Anichini A, Parmiani G (1998) Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4:75–85

    PubMed  CAS  Google Scholar 

  4. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS (2001) Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 97:2923–2931

    Article  PubMed  CAS  Google Scholar 

  5. Borowsky AD, Namba R, Young LJT, Hunter KW, Hodgson JG, Tepper CG, McGoldrick ET, Muller WJ, Cardiff R, Gregg JP (2005) Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis 22:47–58

    Article  PubMed  CAS  Google Scholar 

  6. Cao YA, Bachmann MH, Beilhack A, Yang Y, Tanaka M, Swijnenburg RJ, Reeves R, Taylor-Edwards C, Schulz S, Doyle TC, Fathman CG, Robbins RC, Herzenberg LA, Negrin RS, Contag CH (2005) Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation 80:134–139

    Article  PubMed  Google Scholar 

  7. Cao YA, Wagers AJ, Beilhack A, Dusich J, Bachmann MH, Negrin RS, Weissman IL, Contag CH (2004) Shifting foci of hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci USA 101:221–226

    Article  PubMed  CAS  Google Scholar 

  8. Car BD, Eng VM, Lipman JM, Anderson TD (1999) The toxicology of interleukin-12: a review. Toxicol Pathol 27:58–63

    Article  PubMed  CAS  Google Scholar 

  9. Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ, Colombo MP, Forni G (1997) Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 89:1049–1058

    Article  PubMed  CAS  Google Scholar 

  10. Colombo MP, Trinchieri G (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:155–168

    Article  PubMed  CAS  Google Scholar 

  11. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13:4677–4685

    Article  PubMed  CAS  Google Scholar 

  12. Dudley ME, Rosenberg SA (2007) Adoptive cell transfer therapy. Semin Oncol 34:524–531

    Article  PubMed  Google Scholar 

  13. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS (2003) Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101:640–648

    Article  PubMed  CAS  Google Scholar 

  14. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115:1616–1626

    Article  PubMed  CAS  Google Scholar 

  15. Giroux M, Denis F (2005) CD1d-unrestricted human NKT cells release chemokines upon Fas engagement. Blood 105:703–710

    Article  PubMed  CAS  Google Scholar 

  16. Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB (2003) Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 21:2564–2573

    Article  PubMed  CAS  Google Scholar 

  17. Heinzerling L, Dummer R, Pavlovic J, Schultz J, Burg G, Moelling K (2002) Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice. Exp Dermatol 11:232–240

    Article  PubMed  CAS  Google Scholar 

  18. Introna M, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J, Rambaldi A (2006) Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 38:621–627

    Article  PubMed  CAS  Google Scholar 

  19. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, Weber J (2001) Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 19:3836–3847

    PubMed  CAS  Google Scholar 

  20. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS (2005) A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11:181–187

    Article  PubMed  Google Scholar 

  21. Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS (2002) Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8:3686–3695

    PubMed  CAS  Google Scholar 

  22. Lu PH, Negrin RS (1994) A novel population of expanded human CD3+ CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153:1687–1696

    PubMed  CAS  Google Scholar 

  23. Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, D’Amico G (2006) Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol 34:1219–1229

    Article  PubMed  CAS  Google Scholar 

  24. Mazzolini G, Alfaro C, Sangro B, Feijoo E, Ruiz J, Benito A, Tirapu I, Arina A, Sola J, Herraiz M, Lucena F, Olague C, Subtil J, Quiroga J, Herrero I, Sadaba B, Bendandi M, Qian C, Prieto J, Melero I (2005) Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 23:999–1010

    Article  PubMed  CAS  Google Scholar 

  25. Mule JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225:1487–1489

    Article  PubMed  CAS  Google Scholar 

  26. Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, Karimi M, Negrin RS (2008) In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 112:2563–2574

    Article  PubMed  CAS  Google Scholar 

  27. Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA (2005) Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105:241–250

    Article  PubMed  CAS  Google Scholar 

  28. Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC (1999) Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902–908

    PubMed  CAS  Google Scholar 

  29. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299–308

    Article  PubMed  CAS  Google Scholar 

  30. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318–1321

    Article  PubMed  CAS  Google Scholar 

  31. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159–1166

    Article  PubMed  CAS  Google Scholar 

  32. Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D (1999) Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81:1009–1016

    Article  PubMed  CAS  Google Scholar 

  33. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21:1673–1679

    PubMed  CAS  Google Scholar 

  34. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139–149

    Article  PubMed  CAS  Google Scholar 

  35. Thorne SH, Negrin RS, Contag CH (2006) Synergistic antitumor effects of immune cell-viral biotherapy. Science 311:1780–1784

    Article  PubMed  CAS  Google Scholar 

  36. Tsung K, Meko JB, Tsung YL, Peplinski GR, Norton JA (1998) Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J Immunol 160:1369–1377

    PubMed  CAS  Google Scholar 

  37. Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA (2001) Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8 + NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 7:532–542

    Article  PubMed  CAS  Google Scholar 

  38. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS (2004) Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103:3065–3072

    Article  PubMed  CAS  Google Scholar 

  39. Wajchman HJ, Pierce CW, Varma VA, Issa MM, Petros J, Dombrowski KE (2004) Ex vivo expansion of CD8+ CD56+ and CD8+. Cancer Res 64:1171–1180

    Article  PubMed  CAS  Google Scholar 

  40. Weiss GR, O’Donnell MA, Loughlin K, Zonno K, Laliberte RJ, Sherman ML (2003) Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother 26:343–348

    Article  PubMed  CAS  Google Scholar 

  41. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH (2007) Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7:1705–1721

    Article  PubMed  CAS  Google Scholar 

  42. Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX, Li YQ, Chen SP, Wu PH, Xia JC (2008) Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 31:63–71

    Article  PubMed  Google Scholar 

  43. Zoll B, Lefterova P, Csipai M, Finke S, Trojaneck B, Ebert O, Micka B, Roigk K, Fehlinger M, Schmidt-Wolf GD, Huhn D, Schmidt-Wolf IG (1998) Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother 47:221–226

    Article  PubMed  CAS  Google Scholar 

  44. Zoll B, Lefterova P, Ebert O, Huhn D, Von Ruecker A, Schmidt-Wolf IG (2000) Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation. Cytokine 12:1385–1390

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Imaging Program, Departments of Pediatrics, Radiology, and Microbiology and Immunology, Stanford University School of Medicine, Clark Center, East Wing E150, 318 Campus Drive, Stanford, CA, 94305-5439, USA

    Mike W. Helms, Jennifer A. Prescher, Yu-An Cao, Steven Schaffert & Christopher H. Contag

Authors
  1. Mike W. Helms
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer A. Prescher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu-An Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven Schaffert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher H. Contag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher H. Contag.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 315 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Helms, M.W., Prescher, J.A., Cao, YA. et al. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 59, 1325–1334 (2010). https://doi.org/10.1007/s00262-010-0860-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-010-0860-y

Keywords

Search

Navigation